APC
PLX icon

Aspire Private Capital’s Protalix BioTherapeutics PLX Stock Holding History

Aspire Private Capital’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-400
Closed -$2K – 619
2021
Q1 		$2K Buy
+400
New +$1.86K ﹤0.01% 476

Other funds holding PLX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Aspire Private Capital's PLX Position: Q2 2021 in Review

Aspire Private Capital sold out of Protalix BioTherapeutics (PLX) in Q2 2021, closing a stake of 400 shares — an estimated $2K sold.

Aspire Private Capital first reported a position in PLX in Q1 2021 and held it in 1 quarter. The position peaked at $2K in Q1 2021. 33 funds tracked by Wall St. Rank hold PLX as of Q2 2021.

  • Aspire Private Capital reported no remaining Protalix BioTherapeutics position as of Q2 2021 after selling out during the quarter.
  • Aspire Private Capital sold 400 Protalix BioTherapeutics shares in Q2 2021, an estimated $2K.
  • Aspire Private Capital first reported a position in Protalix BioTherapeutics in Q1 2021 and held it in 1 quarter.
  • Aspire Private Capital's Protalix BioTherapeutics position peaked at $2K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2021.

Based on Aspire Private Capital's 13F filing for Q2 2021, filed 9 Aug 2021.